Interaction of 11 cisplatin analogues with DNA: Characteristic pattern of damage with monofunctional analogues

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1354, Issue 3, 1997, Pages 261-271

  Murray, Vincent ^a   Whittaker, Joanne ^a   Temple, Mark D ^a   McFadyen, W David ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CHIP; Cisplatin; DNA damage; Plasmid pUC19; Sequence specificity; Tetraplatin

Indexed keywords

BIS(CYCLOHEXYLAMINE)DICHLOROPLATINUM(II); CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; DICHLORO(1,2 DIAMINOCYLOHEXANE)PLATINUM(II); DICHLOROBIS(ISOPENTYLAMINE)PLATINUM(II); DICHLOROBIS(ISOPROPYLAMINE)PLATINUM(II); TETRAPLIN; UNCLASSIFIED DRUG;

ARTICLE; DNA DAMAGE; DNA SEQUENCE; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BUFFERS; CISPLATIN; DNA; DNA ADDUCTS; DNA DAMAGE; HEPES; MOLECULAR SEQUENCE DATA; ORGANOPLATINUM COMPOUNDS; OXIDATION-REDUCTION; TROMETHAMINE;

EID: 0031443757     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(97)00087-0     Document Type: Article

References (26)

1. Loeher P.J., Einhorn L.H. Ann. Intern. Med. 100:1984;704-713.
2. Bruhn S.L., Toney J.H., Lippard S.J. Prog. Inorg. Chem. Bioinorg. Chem. 38:1991;478-517.
3. Dabrowiak J.C., Bradner W.T. Prog. Med. Chem. 24:1987;129-158.
4. Christian M.C. Semin. Oncol. 19:1992;720-733.
5. Harrap K.R. Cancer Res. 55:1995;2761-2768.
6. J. Reedijk, Chem. Commun. (1996) 801-806.
7. Ponti M., Forrow S.M., Souhami R.L., D'Incalci M.D., Hartley J.A. Nucleic Acids Res. 19:1991;2929-2933.
8. Murray V., Motyka H., England P.R., Wickham G., Lee H.O., Denny W.A., McFadyen W.D. J. Biol. Chem. 267:1992;18805-18809.
9. Murray V., Motyka H., England P.R., Wickham G., Lee H.O., Denny W.A., McFadyen W.D. Biochemistry. 31:1992;11812-11817.
10. Comess K.M., Burstyn J.N., Essigmann J.M., Lippard S.J. Biochemistry. 31:1992;3975-3990.
11. Braddock P.D., Connors T.A., Jones M., Khokhar A.R., Melzack D.H., Tobe M.L. Chem-Biol. Interact. 11:1975;145-161.
12. Anderson W.K., Quagliato D.A., Haugwitz R.D., Narayanan V.L., Wolpert-DeFilippes M.K. Cancer Treat. Rep. 70(B):1986;997-1002.
13. Vollano J.F., Al-Baker S., Dabrowiak J.C., Schurig J.E. J. Med. Chem. 30:1987;716-719.
14. Pinto A.L., Lippard S.J. Proc. Natl. Acad. Sci. USA. 82:1985;4616-4619.
15. Hollis S.L., Amundsen A.R., Stern E.W. J. Med. Chem. 32:1989;128-136.
16. Barnard C.F.J., Hydes P.C., Griffiths W.P., Mills O.S. J. Chem. Research. (M):1983;2801-2860.
17. Harrison R.C., McAuliffe C.A., Zaki A.M. Inorg. Chem. Acta. 46:1980;L15-L16.
18. Mahal G., Van Eldik R. Inorg. Chim. Acta. 127:1987;203-208.
19. Murray V. Nucleic Acids Res. 17:1989;8889.
20. Knox R.J., Friedlos F., Lydall D.A., Roberts J.J. Can. Res. 46:1986;1972-1979.
21. Pendyala L., Arakali A.V., Sansone P., Cowens J.W., Creaven P.J. Can. Chemother. Pharmacol. 27:1990;248-250.
22. Eastman A. Biochem. Pharmacol. 36:1987;4177-4178.
23. Novakova O., Vrana O., Kiseleva V.I., Brabec V. Eur. J. Biochem. 228:1995;616-624.
24. Clark J.M. Nucleic Acids Res. 16:1988;9677-9686.
25. Brabec V., Leng M. Proc. Natl. Acad. Sci. USA. 90:1993;5345-5349.
26. Denny W.A. Anti-Cancer Drug Design. 4:1989;241-263.